In vivo evaluation of PEGylated 64Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 5, 2016, Pages 941-952

  Petersen, Anncatrine Luisa ^a   Henriksen, Jonas Rosager ^a   Binderup, Tina ^b   Elema, Dennis Ringkjøbing ^a   Rasmussen, Palle Hedengran ^a   Hag, Anne Mette ^b   Kjær, Andreas ^b   Andresen, Thomas Lars ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer imaging; Diagnostic; Nanoparticle; PET; Radiotherapy; Theranostic

Indexed keywords

COPPER 64; LIPOSOME; LUTETIUM 177; PHOSPHOLIPID; TETRAXETAN; COPPER; LUTETIUM; MACROGOL DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYCLOTRON; DIAGNOSTIC IMAGING; DOSIMETRY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RADIATION DOSE; RADIOACTIVITY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; CHEMISTRY; NEUROENDOCRINE TUMORS; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; HUMANS; LIPOSOMES; LUTETIUM; MICE; MICE, NUDE; NEUROENDOCRINE TUMORS; POLYETHYLENE GLYCOLS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84949523492     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3272-6     Document Type: Article

References (37)

1. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.
2. Hellwig D, Gröschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13–21.
3. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–9.
4. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 2007;78:206–12.
5. 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol. 2009;192:W156–60.
6. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79–83.
7. 18F-FDG PET. J Nucl Med. 2010;51:704–12.
8. 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2008;27:52–61.
9. Ravindra V, Botkin C, Yost P, Osman M. Incidental diagnosis of prostate cancer in FDG PET/CT: An initial experience. J Nucl Med. 2007;48:474P.
10. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274–92.
11. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858–902.
12. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res. 2009;42:832–41.
13. 67Cu. Proc Natl Acad Sci U S A. 1996;93:6814–8.
14. Binderup T, Knigge U, Mogensen AM, Hansen CP, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223–32.
15. Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Muller-Brand J, Herskind BK, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93:189–96.
16. Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21:787–94.
17. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med. 2003;30:417–22.
18. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85:6949–53.
19. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991;1066:29–36.
20. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–7.
21. 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: The effect of the extent of PEGylation. Cancer Biother Radiopharm. 2005;20:620–8.
22. 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med. 2009;50:2073–81.
23. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
24. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer. 2000;83:684–8.
25. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials. 2011;32:2334–41.
26. Henriksen JR, Andresen TL. Thermodynamic profiling of peptide membranes interactions by isothermal titration calorimetry: a search for pores and micelles. Biophys J. 2011;101:100–9.
27. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.
28. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Can Res. 2001;7:243–54.
29. Gabizon A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res. 2001;7:223–5.
30. Vallabhajosula S. Molecular imaging: radiopharmaceuticals for PET and SPECT. Berlin Heidelberg: Springer; 2009.
31. Tonkopi E, Ross AA, MacDonald A. CT dose for whole-body PET/CT examinations. AJR Am J Roentgenol. 2013;201:257–63.
32. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–74.
33. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev. 2008;60:1329–46.
34. 177Lu-pegylated liposomes conjugates in tumor-bearing mice. Nucl Instrum Meth A. 2006;569:533–7.
35. Gritmon TF, Goedken MP, Choppin GR. The complexation of lanthanides by aminocarboxylate ligands – I. Stability constants. J Inorg Nucl Chem. 1977;39:2021–3.
36. Cacheris WP, Nickle SK, Sherry AD. Thermodynamic study of lanthanide complexes of 1,4,7-triazacyclononane-N,N′,N″,N‴-tetraacetic acid. Inorg Chem. 1987;26:958–60.
37. 177Lu DOTA-NOC. Cancer Biother Rad. 2007;22:406–16.